Jennifer Effie Amengual

8PUBLICATIONS
47CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 09, 2026
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

Catherine Diefenbach, Opeyemi Jegede, Victoria Wang

|Oct 24, 2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.

James N Gerson, Elizabeth Handorf, Diego Villa

|Jul 17, 2023
Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma.

Xiao Chen, Yinglu Li, Fang Zhu

|Aug 26, 2022
Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma.

Yun Kyoung Ryu, Edd C Ricker, Craig R Soderquist

|Feb 08, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.

Grzegorz S Nowakowski, Fangxin Hong, David W Scott

|Nov 17, 2017
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.

Jennifer E Amengual, Renee Lichtenstein, Jennifer Lue

Pageof 2

Frequent Collaborators

2 joint publications

David W Scott

2 joint publications

Jonathon B Cohen

2 joint publications

Lale Kostakoglu

1 joint publications

Grzegorz S Nowakowski